Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors.
about
Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cellsOncogenomics and the development of new cancer therapiesSuppression of expression of heat shock protein 70 by gefitinib and its contribution to pulmonary fibrosisRecent developments in cancer chemotherapy oriented towards new targets.An approach to evaluating drug-nutrient interactions.Selective inhibition of TNF-alpha-induced activation of mitogen-activated protein kinases and metastatic activities by gefitinib.The Pharmacogenetic Rescue of Side-Lined Anticancer Drugs to the Front-Line: Gefitinib as a Case Example.hEGR1 is induced by EGF, inhibited by gefitinib in bladder cell lines and related to EGF receptor levels in bladder tumours.Reversal of multidrug resistance by gefitinib via RAF1/ERK pathway in pancreatic cancer cell line.Interstitial lung disease associated to erlotinib treatment: a case report.Combined treatment with EGFR inhibitors and arsenite upregulated apoptosis in human EGFR-positive melanomas: a role of suppression of the PI3K-AKT pathway.Pharmacological characterization of MP-412 (AV-412), a dual epidermal growth factor receptor and ErbB2 tyrosine kinase inhibitor.Active antimetastatic immunotherapy in Lewis lung carcinoma with self EGFR extracellular domain protein in VSSP adjuvant.Overexpression of the Axl tyrosine kinase receptor in cutaneous SCC-derived cell lines and tumours.
P2860
Q24810622-FB6ED03A-723B-44C2-BE4C-EBEC1517A1A3Q28263634-2A08A600-CFC4-4084-85C8-547FED853D4AQ28477887-295E46FF-2085-464B-9210-6CEAE37E4AC6Q36150860-BDBEF60C-CB0C-4F8C-81C3-F4DEC0BE0AB4Q36320632-62A45573-440B-46EF-9614-F7B2F7284F32Q36616873-08589060-8F42-4F5F-86F9-E440E7E50BD3Q37838120-29766DEC-C305-4D0E-836F-3781D476974FQ38304521-D8C621CE-389A-4D94-82F5-F93539391B06Q39294074-25B1E990-F7ED-40BE-AEB8-475F8CA0CCCAQ39488527-4AF557DB-A77A-4BA4-BAAD-160A0E788224Q39559565-B4B7565C-4A5B-43AD-960D-168CC01D9E99Q40077599-2ED56F83-EB27-4546-9413-2DAB30C7FF2DQ40255826-7C78C2D7-477E-4E00-A1A6-877B488F0E8FQ43200288-FD383F93-E4D7-40BC-BC7B-EDF8EB6D9F2A
P2860
Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors.
@ast
Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors.
@en
type
label
Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors.
@ast
Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors.
@en
prefLabel
Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors.
@ast
Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors.
@en
P2860
P921
P356
P1476
Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors.
@en
P2093
G Blackledge
S Averbuch
P2860
P2888
P304
P356
10.1038/SJ.BJC.6601550
P407
P577
2004-02-01T00:00:00Z
2004-02-09T00:00:00Z
P5875
P6179
1000716374